President Donald Trump announced Wednesday he will nominate Dr. Heidi Overton, a 37-year-old physician and current White House domestic policy adviser, to lead the Food and Drug Administration (FDA). The nomination comes three months after former commissioner Marty Makary resigned from the post. Senate Health Committee Chair Bill Cassidy (R-La.) responded to the news by criticizing Overton's involvement in a recent executive order concerning childhood vaccine schedules, describing her role as "almost disqualifying."
Overton, a Johns Hopkins-trained surgeon, joined the Trump administration in 2019 during her residency to assist with the COVID-19 response. She later served as vice chair and chief policy officer at the America First Policy Institute before returning to the White House as deputy assistant for domestic policy. In her current role, she has coordinated health policy between agencies including the FDA, CDC, and USDA, working on initiatives ranging from drug pricing to federal nutrition guidelines.
The nomination has faced immediate pushback from several directions. Senator Cassidy cited concerns regarding Overton’s "lack of managerial experience" and her support for the August 10 executive order that aimed to reduce and separate childhood vaccine schedules. Additionally, Senator Patty Murray (D-Wash.) stated she would oppose the nomination, citing Overton's past advocacy for restricting access to the abortion medication mifepristone. Within the "Make America Healthy Again" (MAHA) movement, some activists expressed frustration over Overton’s previous support for protecting the manufacturing of the weedkiller glyphosate.
Supporters, including Health and Human Services Secretary Robert F. Kennedy Jr., have defended her record. Kennedy praised her "strategic leadership" and "meticulous attention to detail," despite noting that their past policy discussions were sometimes "frustrating." White House Chief of Staff Susie Wiles also defended Overton, stating her oversight was necessary to ensure executive directives were "medically sound" and "legally durable." If confirmed, Overton would oversee an agency with more than 16,000 employees responsible for regulating the nation's food, tobacco, and pharmaceutical industries.
The scale of the agency's impact is significant, with the FDA managing a workforce of over 16,000 employees and negotiating user fees with the pharmaceutical industry that fund roughly half of its product review work. For individual citizens, the commissioner's priorities can manifest in concrete changes to public health guidance, such as the childhood vaccine schedules mentioned by Senator Cassidy or federal nutrition guidelines that recently shifted focus toward proteins and whole foods. The outcome of this nomination will determine who holds the authority to implement these policies and manage the agency's multi-billion dollar regulatory responsibilities.
The confirmation process will test the internal dynamics of the Republican-led Senate. Because Senator Cassidy chairs the committee that oversees the FDA, his stated opposition makes her path to confirmation difficult, as he could join Democrats to block her in committee. Other key votes include Republican Senators Susan Collins and Lisa Murkowski, who have previously supported abortion rights. The proceedings are expected to begin in the coming months, though a specific date for a committee hearing has not yet been reported. Until a new commissioner is confirmed, the FDA continues to operate under interim leadership.